M. Mistrik et al., Allogeneic BMT for haematological disorders: Single centre experience of University Hospital Bratislava, BONE MAR TR, 22, 1998, pp. S67-S70
Citations number
7
Categorie Soggetti
Hematology,"Medical Research Diagnosis & Treatment
Data on 65 sibling bone marrow transplantations (BMT) for various hematolog
ical disorders are reported. 51 patients had leukemia, 8 severe aplastic an
emia, 4 myelodysplastic syndrome, one suffered from non-Hodgkin lymphoma an
d one from myeloid metaplasia. All but two patients have engrafted. Overall
, 43 (66%) of 65 patients were alive 0,03 - 7,2 years (median not reached)
as of June 23, 1997. Median time of observation was 13 months. Outcome of s
tandard risk patients was significantly better than that of high risk patie
nts (p=0,006). Our data confirm, that sibling BMT is an effective treatment
modality with acceptable toxicity for younger patients with an early stage
of serious hematological disorders.